IRMD Iradimed Corp
Price (delayed)
$52.72
Market cap
$670.34M
P/E Ratio
34.68
Dividend/share
$0.62
EPS
$1.52
Enterprise value
$618.26M
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system
Highlights
The company's debt has shrunk by 92% YoY and by 41% QoQ
Iradimed's equity has increased by 22% YoY and by 4.1% QoQ
Iradimed's quick ratio has soared by 94% YoY but it has decreased by 4.2% from the previous quarter
IRMD's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 65.9 but 8% higher than its last 4 quarters average of 32.7
Key stats
What are the main financial stats of IRMD
Market
Valuations
Earnings
Shares outstanding
12.72M
Market cap
$670.34M
Enterprise value
$618.26M
Price to earnings (P/E)
34.68
Price to book (P/B)
7.7
Price to sales (P/S)
9.12
EV/EBIT
25.47
EV/EBITDA
24.64
EV/Sales
8.44
Revenue
$73.24M
Gross profit
$56.35M
Operating income
$21.96M
Net income
$19.23M
EBIT
$24.28M
EBITDA
$25.09M
Free cash flow
$16.81M
Per share
Balance sheet
Liquidity
EPS
$1.52
EPS diluted
$1.5
Free cash flow per share
$1.33
Book value per share
$6.85
Revenue per share
$5.78
TBVPS
$7.52
Total assets
$98.33M
Total liabilities
$11.51M
Debt
$154,688
Equity
$86.82M
Working capital
$66.73M
Debt to equity
0
Current ratio
8.84
Quick ratio
7.38
Net debt/EBITDA
-2.08
Margins
Efficiency
Dividend
EBITDA margin
34.3%
Gross margin
76.9%
Net margin
26.3%
Operating margin
30%
Return on assets
20.8%
Return on equity
23.6%
Return on invested capital
73.2%
Return on capital employed
27%
Return on sales
33.1%
Dividend yield
1.18%
DPS
$0.62
Payout ratio
40.8%
IRMD stock price
How has the Iradimed stock price performed over time
Intraday
-1.37%
1 week
-0.11%
1 month
-2.21%
1 year
23.44%
YTD
-4.15%
QTD
0.46%
Financial performance
How have Iradimed's revenue and profit performed over time
Revenue
$73.24M
Gross profit
$56.35M
Operating income
$21.96M
Net income
$19.23M
Gross margin
76.9%
Net margin
26.3%
The company's revenue rose by 12% YoY and by 2.7% QoQ
Iradimed's net income has increased by 12% YoY and by 3.3% from the previous quarter
The gross profit is up by 12% YoY and by 2.5% QoQ
The company's operating income rose by 10% YoY and by 3% QoQ
Growth
What is Iradimed's growth rate over time
Valuation
What is Iradimed stock price valuation
P/E
34.68
P/B
7.7
P/S
9.12
EV/EBIT
25.47
EV/EBITDA
24.64
EV/Sales
8.44
IRMD's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 65.9 but 8% higher than its last 4 quarters average of 32.7
Iradimed's EPS has increased by 12% YoY and by 2.7% QoQ
Iradimed's equity has increased by 22% YoY and by 4.1% QoQ
The price to book (P/B) is 18% higher than the 5-year quarterly average of 6.6 and 4% higher than the last 4 quarters average of 7.5
The company's revenue rose by 12% YoY and by 2.7% QoQ
The price to sales (P/S) is 6% higher than the last 4 quarters average of 8.7
Efficiency
How efficient is Iradimed business performance
Iradimed's return on invested capital has decreased by 6% YoY and by 4.3% QoQ
Iradimed's return on equity has decreased by 4.1% YoY
Dividends
What is IRMD's dividend history
DPS
$0.62
Dividend yield
1.18%
Payout ratio
40.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Iradimed financials performed over time
Iradimed's quick ratio has soared by 94% YoY but it has decreased by 4.2% from the previous quarter
The current ratio has surged by 90% year-on-year but it has declined by 4% since the previous quarter
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
The company's debt has shrunk by 92% YoY and by 41% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.